Here are four things to know:
1. The study will test the ALLOB, the company’s allogeneic bone-cell therapy product.
2. Bone Therapeutics anticipates having efficacy and safety data for the 32 patients by mid-2019.
3. The study will follow the patients for 12 months.
4. The interim results of the study revealed bone formation and pain improvement in patients with ALLOB.
More articles on biologics:
Positive clinical trial results for human dermal fibroblast injection CybroCell: 7 key insights
Stempeutics Research inks deal with Alkem Laboratories for osteoarthritis drug: 3 insights
Bioventus to be sole US distributor of Supartz Fx through May 2028 — 3 things to know
